Biomarkers for early detection and optimized treatment for transitional cell carcinoma.
作者信息
Freedland S J, Bui M H, Chao D, Pantuck A J, Zisman A, Belldegrun A S
出版信息
Rev Urol. 2001 Fall;3(4):210-2.
Abstract
摘要
相似文献
1
Biomarkers for early detection and optimized treatment for transitional cell carcinoma.
Rev Urol. 2001 Fall;3(4):210-2.
2
Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder.
J Urol. 1998 Feb;159(2):394-8. doi: 10.1016/s0022-5347(01)63930-2.
3
Cytokeratin 20: a new marker for early detection of bladder cell carcinoma?
J Urol. 1998 Dec;160(6 Pt 1):1971-4.
4
NMR-based metabolomics study of canine bladder cancer.
Biochim Biophys Acta. 2012 Nov;1822(11):1807-14. doi: 10.1016/j.bbadis.2012.08.001. Epub 2012 Aug 8.
5
The role of nuclear matrix protein 22 in the detection of persistent or recurrent transitional-cell cancer of the bladder.
World J Urol. 1997;15(2):107-11. doi: 10.1007/BF02201981.
6
Bladder cancer: translating molecular genetic insights into clinical practice.
Hum Pathol. 2011 Apr;42(4):455-81. doi: 10.1016/j.humpath.2010.07.007. Epub 2010 Nov 24.
7
Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma.
Oncotarget. 2015 May 30;6(15):13539-49. doi: 10.18632/oncotarget.3841.
8
Monoclonal antibodies against transitional cell carcinoma for detection of malignant urothelial cells in bladder washing.
J Urol. 1985 Aug;134(2):260-5. doi: 10.1016/s0022-5347(17)47118-7.
9
Transitional cell metaplasia of fallopian tube fimbriae: a potential mimic of early tubal carcinoma in risk reduction salpingo-oophorectomies from women With BRCA mutations.
Am J Surg Pathol. 2009 Jan;33(1):111-9. doi: 10.1097/PAS.0b013e31817d74a7.
10
Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.
J Urol. 2007 Feb;177(2):481-7; discussion 487. doi: 10.1016/j.juro.2006.09.038.
本文引用的文献
1
Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study.
Urol Oncol. 1995 May-Jun;1(3):119-26. doi: 10.1016/1078-1439(95)00041-f.
2
Cancer statistics, 2001.
CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36. doi: 10.3322/canjclin.51.1.15.
3
Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924.
J Clin Oncol. 2001 May 15;19(10):2638-46. doi: 10.1200/JCO.2001.19.10.2638.
4
Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial.
J Natl Cancer Inst. 2001 Apr 18;93(8):597-604. doi: 10.1093/jnci/93.8.597.
5
Biomarker risk assessment and bladder cancer detection in a cohort exposed to benzidine.
J Natl Cancer Inst. 2001 Mar 21;93(6):427-36. doi: 10.1093/jnci/93.6.427.
6
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.
J Clin Oncol. 2000 Sep;18(17):3068-77. doi: 10.1200/JCO.2000.18.17.3068.
7
Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: influence on recurrence, progression and survival.
J Urol. 1984 Jul;132(1):27-9. doi: 10.1016/s0022-5347(17)49449-3.
Zotero 插件